Ignite Creation Date:
2024-05-05 @ 6:40 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00524693
Status:
COMPLETED
Last Update Posted:
2007-09-05
First Post:
2007-09-04
Brief Title:
Montelukast in Acute RSV Bronchiolitis
Sponsor:
Ziv Hospital
Organization:
Ziv Hospital
Study Overview
Official Title:
A Double-Blind Placebo Controlled Randomized Trial of Montelukast in Acute Respiratory Syncytial Virus Bronchiolitis
Status:
COMPLETED
Status Verified Date:
2007-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
There is evidence of inflammatory mechanisms in RSV bronchiolitis with increased cysteinyl-leukotrienes cys-LT Recently specific cys-LT receptor antagonists - montelukast Singulair approved for use in infants as granule sachets have become available We evaluated the effect of Singulair on clinical progress and on cytokine profiles in the acute phase of RSV bronchiolitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None